Drug Profile
Research programme: Src kinase inhibitors - Athenex
Alternative Names: KX-2377Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Kinex Pharmaceuticals
- Developer Athenex
- Class Small molecules
- Mechanism of Action Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sensorineural hearing loss